Gain-of-function alterations in CRLF2 are identified in about 5% of pediatric and adult B-ALL overall and in up to 60% of B-ALL arising in patients with Down syndrome, but so far not in any other lymphoid malignancy [121,122,123,124,125]. This evidence concerns the gene CRLF2 and precursor B-cell acute lymphoblastic leukemia.